Herbst RS - Search Results

1

Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR Jr, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Kim ES, et al. Among authors: herbst rs. J Thorac Oncol. 2013 Dec;8(12):1519-28. doi: 10.1097/JTO.0000000000000009. J Thorac Oncol. 2013. PMID: 24189513 Free PMC article. Clinical Trial.

2

Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Strauss GM, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-73-S12-80. Semin Oncol. 1997. PMID: 9331127 Clinical Trial.

3

Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.

Herbst RS, Lilenbaum R. Herbst RS, et al. Semin Oncol. 1999 Oct;26(5 Suppl 16):67-70; discussion 71-2. Semin Oncol. 1999. PMID: 10585011 Review.

4

Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.

Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Herbst RS, et al. Clin Cancer Res. 2000 Mar;6(3):790-7. Clin Cancer Res. 2000. PMID: 10741698

5

9:00-9:15. Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors.

Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. Mullani N, et al. Clin Positron Imaging. 2000 Jul;3(4):151. doi: 10.1016/s1095-0397(00)00063-7. Clin Positron Imaging. 2000. PMID: 11150754

6

Emerging therapies in non-small-cell lung cancer.

Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Among authors: herbst rs. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Free article. Review.

7

Epidermal growth factor receptor biology (IMC-C225).

Kim ES, Khuri FR, Herbst RS. Kim ES, et al. Among authors: herbst rs. Curr Opin Oncol. 2001 Nov;13(6):506-13. doi: 10.1097/00001622-200111000-00014. Curr Opin Oncol. 2001. PMID: 11673692 Review.

8

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.

Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. Kim ES, et al. Among authors: herbst rs. Lung Cancer. 2001 Dec;34(3):427-32. doi: 10.1016/s0169-5002(01)00278-1. Lung Cancer. 2001. PMID: 11714540 Clinical Trial.

9

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.

Herbst RS, Kim ES, Harari PM. Herbst RS, et al. Expert Opin Biol Ther. 2001 Jul;1(4):719-32. doi: 10.1517/14712598.1.4.719. Expert Opin Biol Ther. 2001. PMID: 11727507 Review.

10

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

Herbst RS, Langer CJ. Herbst RS, et al. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36. doi: 10.1053/sonc.2002.31525. Semin Oncol. 2002. PMID: 11894011 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

427 results

Search Page